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ABSTRACT Scleromyxedema or generalized lichen myxedemato-
sus is a rare depositional disorder. Diagnostic criteria encompass 
a generalized papular and sclerodermoid eruption, monoclonal 
gammopathy (paraproteinemia), most often with G-lambda type 
immunoglobulin, a characteristic microscopic triad (mucin de-
position, fibroblast proliferation, fibrosis), and absence of thyroid 
disease. Many internal manifestations of scleromyxedema have 
been described to date, leading to high mortality and morbidity. 
Because the disease is rare, the etiology is not fully understood and 
there is a lack of well-designed studies, so no optimal treatment ex-
ists so far. This paper reports the follow-up on a patient in 5.5-year 
remission after successful intravenous immunoglobulin therapy 
10.5 years since initial diagnosis.
KEYWORDS: scleromyxedema, mucinoses, therapy, intravenous 
immunoglobulin
INTRODUCTION
Scleromyxedema is a rare depositional disorder 
and one of the three subtypes of lichen myxede-
matous (1). The other two are localized and atypical 
forms. The prevalence is the same for both sexes and 
mainly affects adults in their fifties or sixties (2,3). Di-
agnostic criteria encompass a generalized papular 
and sclerodermoid eruption, monoclonal gammopa-
thy (paraproteinemia) most often with G-lambda type 
immunoglobulin, a characteristic microscopic triad 
(mucin deposition, fibroblast proliferation, fibrosis), 
and absence of thyroid disease (2,3). Skin features 
are numerous, widespread, firm, and waxy 2-3 mm 
papules in symmetrical distribution, most commonly 
located on the head, neck, dorsum of the hands and 
forearms, the upper trunk, and thighs (4). Non-tender 
subcutaneous nodules occur rarely (5). Additionally, 
the skin of the face, trunk, and distal extremities is 
thickened, consequently leading to microstomy and 
decreased articular mobility (4). Many internal mani-
festations of scleromyxedema have been described 
to date, including cardiovascular, neurological, rheu-
matological, muscular, pulmonary, renal, gastrointes-
tinal, and ophthalmological (1,2). According to the 
literature, they occur in 70-77% of cases, and morbid-
ity and mortality are therefore high (3). Possible oc-
currence of multiple myeloma in 10% of patients has 
also been described (6). Scleromyxedema can mimic 
systemic scleroderma (7). The etiopathogenesis has 
not yet been fully explained; however, it is known that 
serum from the patient enhances the proliferation of 
dermal fibroblasts and that a yet unspecified factor 
in it is probably responsible, rather than not purified 
ACTA DERMATOVENEROLOGICA CROATICA
25
Baglama et al. Acta Dermatovenerol Croat
IVIg treatment in scleromyxedema   2020;28(1):24-28
immunoglobulin. Mucin and increased collagen de-
positions take place in the dermis (1). Because the 
disease is rare, the etiology is not fully understood 
and there is a lack of well-designed studies, no opti-
mal treatment exists to date. Relying on case reports 
and case series, the European Dermatology Forum 
S1-guideline on the diagnosis and treatment of scle-
rosing diseases of the skin supports the use of intra-
venous immunoglobulin (IVIg) as the first-line therapy 
because it is effective and safe (5). However, it should 
be emphasized that many other therapeutic options 
and drug combinations are sometimes used with 
varying efficiency, for example melphalan, autolo-
gous stem-cell transplantation, thalidomide, systemic 
glucocorticoids, retinoids (isotretinoin, acitretin), hy-
droxychloroquine, cyclosporine, cyclophosphamide, 
methotrexate, 2-chlorodeoxyadenosine, interferon 
alfa-2b, plasmapheresis, electron-beam therapy, 
bortezomib, and extracorporeal photopheresis (1,5).
CASE REPORT
In February 2009, a 64-year-old retired truck driver 
and former chain smoker presented to the doctor’s of-
fice for the first time at the age of 54 with a 1-year his-
tory of gradual thickening and stiffening of the skin 
over the upper extremities, trunk, and face. He also 
complained of bumps on the cheeks, first noticed 10 
months ago, due to which he had undergone several 
excisions at the Otorhinolaryngology Department 
one week prior to the examination. The patient was 
otherwise healthy with no significant medical his-
tory. Examination of the skin of the cheeks, forehead, 
and dorsum of the hands showed diffuse thickening 
with a waxy texture and erythema. Infiltration and 
furrowing produced leonine facies. The skin of the 
back was infiltrated, and longitudinal folds could be 
noticed. Opening of the mouth was restricted, and 
the patient had sclerodactyly 2. Other systems were 
clinically normal. The presentation raised suspicion 
of scleromyxedema. Histopathological analysis of a 
punch biopsy confirmed the diagnosis. WE also ob-
served normal epidermis with dermal proliferation 
of fibroblasts and increased interstitial mucin). Ex-
tended laboratory results were within normal ranges, 
including complete blood count with a differential, 
comprehensive metabolic panel, urine analysis, and 
thyroid examination. Monoclonal gammopathy on 
serum protein electrophoresis was initially absent. 
Tumor markers were negative as well. We carried out 
the investigations listed below to further exclude any 
Figure 1. Histopathological analysis of punch biopsy re-
vealed normal epidermis with dermal proliferation of fibro-
blasts and increased interstitial mucin.
Figure 2. (a) Scleromyxedema: typical leonine facies with erythematous skin. (b) The same patient 10.5 years after the initial 
diagnosis. Minimally indurated skin of the face can be seen, with less prominent longitudinal wrinkles of the forehead.
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systemic involvement of the disease. Abdominal ul-
trasound showed markedly hyperechogenic liver, 
most likely because of fibrotic parenchyma. Due to 
changes in ECG (left heart axis, low R tooth from V1 
to V3, negative T wave and left anterior hemiblock) 
along with detailed cardiac diagnostics, single-vessel 
coronary artery disease was identified and a prescrip-
tion of acetylsalicylic acid, ramipril, and bisoprolol 
was introduced. Chest X-ray, esophageal passage X-
ray, and spirometry were without significant devia-
tions from the normal range. 
When the entire diagnostic process was complet-
ed, we introduced monotherapy with high dose IVIg 
in the dose of 2 g/kg bodyweight, administered over 
4 consecutive days (45 g/day) once monthly. Initially, 
the patient received 6 cycles of IVIg, and gradual clini-
cal improvement was observed after each of them but 
full regression was not achieved. The disease notice-
ably progressed approximately every 3 months, which 
was first observed 4 months after the last of these 6 
cycles when monoclonal IgG type lambda in serum 
immunofixation electrophoresis was also detected 
Figure 4. (a) Induration of the dorsal parts of the hands before initiating therapy with intravenous immunoglobulin. 
(b) Improvement of erythema and edema after successful treatment can be observed.
Figure 3. (a) Longitudinal folds on the back, also known as a Shar-Pei sign. The photo was taken on the patient’s first visit to 
the doctors’ office. (b) The same patient in August 2019. Indurated skin had completely disappeared. 
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for the first time, but further investigations excluded 
hematological disorders. With each reappearance of 
the skin changes, we reintroduced IVIg following the 
same dosing scheme as before, i.e. one cycle of 2 mg/
kg divided over 4 consecutive days. In January 2014, a 
few months after the patients’ retirement, the derma-
tologists decided to repeat regular dosing, this time 
every six weeks, with the usage of the same scheme 
as previously. Almost complete clinical remission was 
achieved after four cycles – erythema in the nasolabi-
al folds could be observed, with minimally indurated 
skin on the face and upper extremities. The patient 
was able to fully open his mouth. In total, the patient 
received 21 IVIg cycles over 5 years.
From April 2014 to the present the patient was 
regularly monitored and required no additional cy-
cles of IVIg. He is currently in clinical remission 10.5 
years after initial diagnosis and has not been receiv-
ing therapy for the last 5.5 years. The last follow-up 
evaluation was performed in August 2019 when a 
punch biopsy from the same site as the first time was 
repeated and revealed non-specific histological find-
ings without dermal mucin deposits on special stain-
ing with alcian blue. Widespread laboratory tests were 
completely normal. Serum protein electrophoresis 
showed still present IgG lambda paraproteinemia, as 
was suspected. On repeated abdominal ultrasound 
examination, liver echogenicity was normal as were 
all other structures, with the exception of bladder 
with walls of uneven contractures and a moderately 
enlarged hypo echogenic prostate. Since 2015, the 
patient has been undergoing regular check-ups by 
urologists for benign prostatic hyperplasia and per-
sistent microscopic hematuria.
DISCUSSION
The patient presented herein was followed-up 
for a period of 10.5 years. He had characteristic skin 
findings and ultimately fulfilled all four criteria for 
diagnosing scleromyxedema, the pathophysiology 
of which is still under debate. As no stable clinical 
improvement was observed until few months after 
his retirement as truck driver, we think ultraviolet ex-
posure had a role in disease pathogenesis, but there 
are case reports in which UVA-1 and PUVA photo-
therapy have led to improvement of the disease. 
However, our theory may be supported by a case 
report written by Kirchberger MC et al. where sclero-
myxedema in a young woman first expressed itself 
after holidays in Egypt as erythema strictly limited 
to photoexposed sites, initially clinically and patho-
logically evaluated as dermatitis solaris and eventu-
ally properly diagnosed once fully expressed (7). No 
other anamnestic data except smoking stand out in 
our patient. As for systemic manifestations, cardio-
vascular problems may be due to the disease itself, 
in which case mucin deposition in the heart vessels 
should be demonstrated, or the overall coincidence 
can be only incidental. Ultrasound liver changes 
vanished over the years, and there was no mention 
of co-occurrence of liver fibrosis in the literature 
reviewed. The same applies to benign prostatic 
hyperplasia. 
Many possible treatments have been mentioned 
to date, all with their own advantages and disadvan-
tages. This case report confirms IVIg can be an effec-
tive and safe therapy for long-term control of sclero-
myxedema. In total, our patient received 21 IVIg cy-
cles from 2010 to 2014. According to the literature, 
some authors discontinued IVIg therapy after reach-
ing complete response and reintroduced it in case 
of a relapse without noticeable lower response rates, 
which is what we did in the case presented here. 
Others advocate an approach with long-term main-
tenance dosing spaced out to every two months, but 
this may be uneconomical (3,8). According to the 
European Dermatology Forum S1-guideline, the use 
of IVIg is initially recommended over a period of six 
months. If no improvement is observed during this 
time, treatment should be discontinued (5). Differ-
ent therapeutic regimens are used, most commonly 
full doses or 2 g/kg once every 4 weeks, divided over 
4-5 consecutive days (3-5). This was the approach 
chosen in our case. A minority of clinicians opt for 
the low dose protocol, i.e. 0.4-0.5 g/kg once monthly, 
with similar outcomes (4). The mechanism of action 
of IVIg is still under debate, with blockage of the Fc 
receptor leading to non-functional phagocytic cells 
or immunomodulatory action including neutraliza-
tion of circulating autoantibodies by anti-idiotype 
antibodies as two of the hypotheses (3,6). Another 
hypothesis claims alternation of metalloproteinases 
is important, resulting in alternation of matrix colla-
gen (6). IVIg improves both cutaneous and extracu-
taneous manifestations, which can also be observed 
in the case presented above with normalization of 
liver echogenicity. Side-effects are usually mild and 
self-limiting. There may, however, be rare but serious 
side-effects, for example anaphylaxis, acute renal 
failure, deep venous thrombosis, pulmonary embo-
lism, stroke, arrhythmia, aseptic meningitis, hemo-
lytic anemia, myocardial ischemia, and transfusion-
related acute lung injury (5,6,9). Their incidence may 
be reduced by the following measures: performing 
an early assessment of risk factors, infusing at a slow 
rate, premedicating, and switching from intravenous 
to subcutaneous immunoglobulin (9). The patient 
presented above tolerated the therapy well. 
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CONCLUSION
In summary, our patient was followed for a period 
of 10.5 years and has currently been in clinical remis-
sion for 5.5 years after cessation of IVIg, which is to our 
knowledge among the longest reported disease-free 
periods. Namely, in the largest retrospective study of 
30 patients with scleromyxedema by Rangioletti et 
al., one of the patients was monitored for a maximum 
of 11 years (3). Moreover, there was also histological 
response in our case. The paraprotein is still detect-
able as was expected from the findings reported so 
far, however, it should be emphasized that there was 
a delay in its appearance. The relapse rate is high af-
ter discontinuation of therapy, so regular follow-up of 
the patient once per year is required.
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